Nancy Whiting

Nancy is the Chief Executive Officer at Recludix Pharma and has an established track record in all phases of drug development. She is a 15-year veteran of Seagen (formerly Seattle Genetics) and most recently served as Executive Vice President of Corporate Strategy. Nancy previously served as Executive Vice President of Late-Stage Development, Senior Vice President of Clinical Development and Medical Affairs, and Head of Experimental Medicine at Seagen. During her tenure at Seagen, she played a central role in the development of ADCETRIS®, PADCEV®, TUKYSA®, and TIVDAK®, in addition to several other pipeline compounds. Prior to her tenure in the biopharmaceutical industry, she had a career in clinical pharmacy serving as a Clinical Oncology Pharmacist at Seattle Cancer Care Alliance, and previously as the Staff Pharmacist for the Bone Marrow Transplant and Acute Leukemia department at Vancouver Hospital. Nancy received her Pharm.D. degree from the University of Washington and a B.S. in Pharmacy from the University of British Columbia.